We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HLN:LSEHaleon PLC Analysis

Data as of 2026-03-10 - not real-time

£373.90

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Haleon plc trades at £373.9, just above its 200‑day SMA (£368.9) and the identified support level (£369.8), suggesting a technical floor that could hold in the near term. The stock is below its 20‑day (£398.3) and 50‑day (£384.7) moving averages and the MACD is bearish, yet the RSI of 38.9 points to oversold conditions and a potential short‑term bounce. Fundamentally, the company delivers strong margins (gross 64.7%, operating 22.9%) and a healthy free cash flow of £1.37 bn, while maintaining a modest payout ratio of 36.8% that supports the 1.88% dividend yield.
Valuation appears stretched: the DCF fair value is only £135.9 versus the market price, and the price‑to‑book ratio exceeds 200×, though the PE of 19.7 is below the industry average of 25.4, indicating relative earnings value. Debt‑to‑equity sits at 52.6% with ample cash, and analysts project a median target of £435, implying roughly 14% upside. The stock benefits from increasing volume and a low beta (‑0.06), but its 30‑day volatility is high at 31.9%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above support (£369.8) with rising volume
  • RSI indicates oversold conditions that may trigger a bounce
  • Bearish MACD and price below short‑term SMAs temper upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst median target of £435 suggests ~14% upside
  • Strong cash generation and sustainable dividend yield
  • Fundamentals (margins, ROE) remain robust despite flat revenue growth

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Resilient global consumer‑health brand portfolio
  • Low sector and currency risk with diversified geographic exposure
  • Stable dividend policy and manageable debt levels support long‑run stability

Key Metrics & Analysis

Financial Health

Revenue Growth0.60%
Profit Margin15.11%
P/E Ratio19.7
ROE10.27%
ROA4.65%
Debt/Equity52.62
P/B Ratio202.4
Op. Cash Flow£2.6B
Free Cash Flow£1.4B
Industry P/E25.4

Technical Analysis

TrendBullish
RSI38.9
Support£369.80
Resistance£416.10
MA 20£398.32
MA 50£384.68
MA 200£368.88
MACDBearish
VolumeIncreasing
Fear & Greed Index79.36

Valuation

Fair Value£135.94
Target Price£426.56
Upside/Downside14.08%
GradeOvervalued
TypeValue
Dividend Yield1.88%

Risk Assessment

Beta-0.06
Volatility31.93%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.